NEW YORK – Burning Rock Biotech reported on Friday morning that its third quarter revenues grew more than 19 percent year over year.
The Chinese precision oncology firm, which completed a $256.2 million IPO in June, reported total revenues of RMB123.9 million (US$18.2 million) for the three months ended September 30, compared to RMB103.7 million in the same period of 2019.